Under the terms of the deal, 23andMe will acquire Lemonaid for $100 million in cash and $300 million in common stock. The transaction is expected to close by the end of the year.

Join The Ecosystem

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}